Home > Boards > US OTC > Biotechs >

TetraLogic Pharmaceuticals Corp. (TLOG)

TLOG RSS Feed
Add TLOG Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 2/21/2021 6:30:33 PM - Followers: 35 - Board type: Free - Posts Today: 0

 

Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer.
To do this efficiently and with a high success rate, we bring together a unique combination of clinical development skills,
a collaborative culture and an extensive industry experience, with a balanced project portfolio.

Medivir is listed on Nasdaq Stockholm's Small Cap list.

UPDATED 04-28-2020
https://www.medivir.com/
https://www.medivir.com/about-us
https://www.medivir.com/our-projects
https://www.medivir.com/our-projects#ProjectsForLicensing

Birinapant

 
EVENTS2020/11/10
Interim Report January - September 2020

 

Read more
EVENTS2020/08/20
Interim Report January - June 2020

 

Read more
EVENTS2020/05/05
Interim Report January - March 2020

 

Read more
EVENTS2020/05/05
Annual General Meeting 2020

The Annual General Meeting 2020 will be held on 5 May at 2pm CET, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm.

Read more
PRESS RELEASE2020/04/15
Medivir announces departure of Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company...

Read more


TetraLogic Pharmaceuticals Corp
 

TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB

Date : 12/29/2016 @ 10:30AM
Source : GlobeNewswire Inc.
Stock : NO^TLOG (TLOG)
Quote :  0.1102  0.0 (0.00%) @ 2:05AM
 
 

TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB


http://ih.advfn.com/p.php?pid=nmona&article=73509938

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary
TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to
Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic 
program, including their clinical stage asset birinapant,
and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the “Sale”) for a purchase price of (i) $12 million payable in
cash at closing plus (ii) milestone payments of up to $153 million based on the development and commercialization of TetraLogic’s
product candidates by Medivir subject to certain conditions and limitations 
described in the Asset Purchase Agreement for the Sale
and (iii) additional earn-out payments based on annual net sales of birinapant, subject to certain conditions and limitations described
in the Asset Purchase Agreement for the Sale as follows:

 

  • the Company will be entitled to 5% of annual net sales from $0 to $500,000,000;
    the Company will be entitled to 7.5% of annual net sales from $500,000,000 to $1,000,000,000; and
    the Company will be entitled to 10% of annual net sales above $1,000,000,000.

Medivir also assumed certain assumed liabilities.

The transaction was approved by the holders of TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders
holding a majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.

Under its agreement with the holders of Senior Notes, the Company will use the $12 million cash proceedsreceived at closing of the Sale to redeem $12 million
in aggregate principal amount of the Senior Notes then outstanding.  
The holders of the Senior Notes have also agreed to extend the maturity date of the
Senior Notes to June 15, 2024 and to receive interest payments in additional Senior Notes in lieu of cash.

The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and
deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.

In connection with the completion of the Sale,
Mr. J. Kevin Buchi,
Dr. Mary Ann Gray,
Mr. Michael Kishbauch,
Mr. Paul Schmitt and
Dr. Andrew Pecora each resigned
as a member of the Board of Directors of the Company, effective December 30, 2016. 
The resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. 
Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as Chief Executive Officer of the Company,

Mr. Richard Sherman resigned as Senior Vice President, Secretary and General Counsel of the Company,
Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as
Chief Operating Officer of the Company. In connection with their resignation, each officer entered into a settlement and release
agreements pursuant to which each received a lump sum settlement in the aggregate
amount previously disclosed in the Company’s Form 8-K filed on November 14, 2016.

Forward-Looking Statements

Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent
and belief or current expectations of TetraLogic and its management team.

Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”,
“expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the
forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including
TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016,
for information regarding risk factors that could affect TetraLogic’s results.

The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly
update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.

      CONTACT:  Richard L. Sherman General Counsel, TetraLogic Pharmaceuticals Corporation  Richard.sherman@tetralogicpharma.com

Primary Logo



http://tetralogicpharma.com/
http://tetralogicpharma.com/clinical-trials/
http://ir.tetralogicpharma.com/
http://tetralogicpharma.com/science/
 

Active Clinical Programs

ONCOLOGY PHASE 1 PHASE 2 PHASE 3
Myelodysplastic Syndromes (MDS) Birinapant    
Cutaneous T-Cell Lymphoma (CTCL) SHAPE    
Ovarian Cancer Birinapant    
INFECTIOUS DISEASE      
Hepatitis B
 

Presentations & Publications

Bioradiations: What Academic Researchers Can Learn from Small Biotechs about Antibody Validation

Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC

> See all Presentations & Publications



http://tetralogicpharma.com/about-us/

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on discovering, acquiring and
developing novel product candidates to treat cancer and infectious diseases. We currently have two clinical-stage product candidates in development:
birinapant and suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE).

Birinapant is designed to mimic the activity of an endogenous protein, the Second Mitochondrial Activator of Caspases, or SMAC,
which is involved in the regulation of the apoptotic process within cells.
Avoidance of apoptosis is a critical step in cancer tumor development and certain infectious diseases.

SHAPE is a histone deacetylase inhibitor, or HDACi. Altered expression of histone deacetylases, or HDACs, has been linked to
tumor development and several drugs approved for systemic use in the treatment of cancers take advantage of this mechanism.




 

PER  IHUB  MGMT 

02-07-2021
DISCLAIMER:  ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
 
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION 
AUTHORS MAY HAVE BUYS OR SELLS  WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.

ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Any




 








 
TLOG
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1936  Sticky Note $TLOG SALES 12-29-2016 AGREEMENT TetraLogic Pharmaceuticals Corporation An mick 01/18/21 02:50:38 PM
#1953   TetraLogic Pharmaceu (TLOG) mick 02/21/21 06:30:33 PM
#1952   Nice gains today! Flygy481 02/19/21 05:45:09 PM
#1951   [-chart]www.stockscores.com/chart.asp?TickerSymbol=TLOG&TimeRange=275&Interval=d mick 02/13/21 02:35:20 PM
#1950   Medivir is raising millions. Tetralogic shareholders are watching. TuesdaySmall 02/09/21 06:21:59 PM
#1949   [-chart]www.stockscores.com/chart.asp?TickerSymbol=TLOG&TimeRange=180&Interval=d mick 02/08/21 11:53:46 PM
#1948   I never said I owned more or less FlySwater 02/07/21 12:59:31 AM
#1947   You own over 3 million shares??? If so TuesdaySmall 02/05/21 09:58:13 PM
#1946   Yawn... Mild accumulation began on December 14th, 3 days FlySwater 02/05/21 08:20:32 PM
#1945   I think TLOG is going to go. Chart TuesdaySmall 02/05/21 03:33:29 PM
#1944   It seems like someone’s been accumulating a lot TuesdaySmall 02/05/21 01:34:40 PM
#1943   Nice to see some shares traded Flygy481 02/05/21 12:21:34 PM
#1942   Looks like accumulation going on. Hopefully there won’t TuesdaySmall 02/02/21 09:10:59 PM
#1941   https://otcbb.swingtradebot.com/equities/TLOG N.Y. , NASDAQ mick 01/31/21 08:29:38 PM
#1940   http://www.stockta.com/cgi-bin/analysis.pl?symb=TLOG mick 01/18/21 03:23:41 PM
#1939   $TLOG Share Structure Outstanding Shares 24,769,083 08/08/2016 mick 01/18/21 02:57:36 PM
#1938   correct after sale i thought 'TetraLogic Pharmaceuticals Corp. (TLOG)' mick 01/18/21 02:55:41 PM
#1937   READING CHANGE TetraLogic Pharmaceuticals Corporation Announces Director A mick 01/18/21 02:54:17 PM
#1936   $TLOG SALES 12-29-2016 AGREEMENT TetraLogic Pharmaceuticals Corporation An mick 01/18/21 02:50:38 PM
#1935   IS DIS OR ????? AGREEMENT WITH $TLOG BYPASS mick 01/18/21 02:44:15 PM
#1934   $TLOG https://investorshub.advfn.com/TetraLogic-Pharmaceuticals-Corp-TLOG-27741 mick 01/18/21 02:36:45 PM
#1933   FlySwater - eventually the truth will come out. TuesdaySmall 01/15/21 12:06:47 AM
#1932   You said it perfectly Flygy481 01/14/21 04:43:10 PM
#1931   I’m not sure what to say about this TuesdaySmall 01/14/21 02:24:18 PM
#1930   If TLOG doesn’t have obligations to file with TuesdaySmall 01/13/21 11:52:07 AM
#1929   It didn’t make sense why TLOG would renegotiate. TuesdaySmall 01/13/21 11:04:04 AM
#1928   This is why the renegotiation happen just the Flygy481 01/13/21 06:50:06 AM
#1927   https://www.medivir.com/investors/press-releases/2021/medivir-enters-into-exclus roctober 01/13/21 12:18:45 AM
#1926   TetraLogic Pharmaceu (TLOG) mick 01/12/21 06:04:35 PM
#1925   Mick are you bot? TuesdaySmall 01/08/21 02:31:49 AM
#1924   Updating Review, Waiting for Royalty,huge reading- TetraLogic Pharmaceutic mick 01/07/21 08:54:13 PM
#1923   IT DOESN'T APPEAR IN SHAREHOLDERS FAVOR 'TuesdaySmall' on mick 01/07/21 08:52:37 PM
#1922   I DID NOT SEE DA NEWS, to 'Flygy481' mick 01/07/21 08:51:04 PM
#1921   TetraLogic Pharmaceu (TLOG) mick 01/07/21 08:50:27 PM
#1920   I’m confused by this news of renegotiated agreement. TuesdaySmall 01/07/21 03:50:34 PM
#1919   I’m not well-versed with this stuff, but, it Flygy481 01/03/21 04:48:06 PM
#1918   https://pennystocks.news/otc/?symbol=TLOG mick 01/03/21 04:09:18 PM
#1917   I KNOW DIS OVERDUE ROYALTY PAYMENT mick 01/03/21 04:08:51 PM
#1916   https://apple.news/AWZM6Y63uT4aaCac-p28fDA Flygy481 01/03/21 08:10:42 AM
#1915   What do ya know!? News! Flygy481 01/02/21 11:33:09 PM
#1914   [-chart]www.stockscores.com/chart.asp?TickerSymbol=TLOG&TimeRange=180&Interval=w mick 01/02/21 03:43:00 PM
#1913   $TLOG LONG OVERDUE ROYALTY PAYMENT mick 01/02/21 02:15:18 PM
#1912   TetraLogic Pharmaceu (TLOG) mick 12/07/20 01:08:25 PM
#1911   TetraLogic Pharmaceu (TLOG) mick 11/24/20 08:22:18 PM
#1910   TetraLogic Pharmaceu (TLOG) mick 10/25/20 05:14:42 PM
#1909   Hello, anybody home??? Flygy481 10/19/20 07:42:24 AM
#1908   TetraLogic Pharmaceu (TLOG) mick 09/24/20 09:22:47 PM
#1907   i hope $TLOG mick 09/24/20 09:22:39 PM
#1906   *yawn* Luckily I dont have much in here, but Kypee 09/18/20 10:45:59 AM
#1905   $TLOG NEWS TO UPDATE SHAREHOLDERS mick 09/05/20 02:45:53 PM
#1904   TetraLogic Pharmaceu (TLOG) mick 09/05/20 02:45:27 PM
PostSubject
Consent Preferences